Today, most men who have localized prostate cancer at diagnosis and who undergo either active surveillance or curative treatment can expect to have a disease-specific survival of at least 10 years 2-4 . Even men with metastatic disease can expect increased survival as new therapeutic agents become available and alternative regimes for existing treatments are tried 5, 6 . Those facts, combined with an overall life expectancy predicted to reach 81.9 years by 2031 7 , result in the reality of long exposure to the ramifications of prostate cancer treatments for patients and their families alike.
INTRODUCTION
Although it is the most common cancer in North American men 1 , prostate cancer is in most cases diagnosed when it is still localized and curable. There are a number of treatment options with comparably good oncologic outcomes, but with particular side-effect profiles. Men treated for prostate cancer embark on a journey with many decision points or "forks in the road" where they must manage uncertainty and ultimately their personal fear of a cancer death.
Curr Oncol, Vol. 19, pp. S37-44; doi: http://dx.doi.org/10.3747/co. 19.1287 decisions after a localized prostate cancer diagnosis. Those preferences are particularly cogent in situations in which several choices of optimal therapy are available. Eliciting preferences and translating them into cancer care is, however, challenging.
The first challenge has to do with basic patient education. Randomized and observational studies investigating patient perceptions of prostate cancer have identified that patients are not well informed about the natural history of prostate cancer, the predictive value of the prostate-specific antigen (psa) blood test, the controversies about psa screening, and the benefits and risks of treatment at all stages [9] [10] [11] [12] . Men who do not receive education about the psa test and its possible sequelae are disturbingly more likely to elect active treatment over observation if prostate cancer is detected by a screening psa test 9 . Furthermore in a survey of men over 50 years of age who had undergone prostate cancer screening, although respondents recalled discussing screening and feeling informed about the rationale, fewer than half could accurately answer one knowledge question about screening 10 . A similar lack of knowledge about treatment side effects has been documented for patients with advanced disease commencing androgen deprivation therapy 13, 14 .
Studies on patient perception and knowledge about medical choices are commonly biased toward well-educated, affluent, white populations. Unsurprisingly, prostate cancer knowledge is particularly poor in less privileged minority groups 15, 16 . Patient comprehension of cancer terminology and treatment options has historically been demonstrated to be poor 17, 18 . Increasing awareness of this situation on the part of health care professionals has led to a proliferation of "patient friendly" flyers, booklets, videos, and Web sites. Unfortunately, the information accessed by patients at many sources has little, if any, quality control and may be neither verified nor accurate. Additionally, patients may misinterpret the information presented 19 , and there is little evidence that the abundance of accessible information has had any positive impact in improving treatment selection or reducing treatment regret.
The reality is that patients repeatedly cite their health care providers as their most important source of information, and they rely on their specialist to inform them about management options 10, 20 . Patient preferences for the communication of an initial diagnosis rely on the "honesty and expertise" of their doctors. How the diagnosis is communicated has been rated as less important 21 . However, once aware of their diagnosis, most patients prefer to take an active or collaborative role with their physician in decision-making. The key information preferences identified by patients to bolster their participation in the decision process are prognosis, stage of disease, treatment options, and side effects 22 .
Treatment advice given by urologists and radiation oncologists about options for prostate cancer therapy tends to be weighted (even biased) toward the specialist's own realm of expertise 23, 24 . During selection of a primary treatment, shared decision-making between physician and patient can be stressful and problematic for the patient because there is little evidence to favour one treatment over another 25 . Ideally, an individual's choice of treatment should reflect an evaluation of the benefits, harms, costs, and inconveniences compared with the available alternatives. In reality, such decisions are often subjective, and a lack of information may affect the patient's ability to understand the tradeoffs. Age, the family physician's opinion, current health, level of sexual function, and personal contact with family or friends diagnosed with prostate cancer all significantly affect a patient's treatment choice [25] [26] [27] .
Patients have preconceptions and, often, unrealistic expectations of treatment outcomes despite receiving information about risks and benefits 19 . Although providing more resources and taking extra time to support and intensively counsel patients may intuitively seem to be appropriate, recent evidence suggests that this approach alone does not eliminate unrealistic expectations 28 . And so, given that the strongest predictor of treatment choice remains the type of physician seen at enrolment 29 , the physician should not necessarily be considered to be the one biasing the treatment; rather, patients may be choosing to see a specialist who favours their preconceptions and expectations.
In the literature, many studies of patient preference report high levels of patient satisfaction with prostate cancer treatment choices 26, 30, 31 . There are, however, potential sources of bias in those studies. In particular, patients who respond to such surveys are likely to be well-motivated and educated. Respondents are similarly likely to have had a satisfactory response to treatment and thus to respond positively to retrospective questions concerning treatment regret. Patients may speak positively about a treatment outcome when they have nothing to compare it with. The concept of cognitive conflict explains the reality that they do not know what would have happened if they had chosen another treatment. Caregivers must be aware that this uncertainty may result in deferred psychological distress that may manifest some time after treatment.
Patients can be biased toward novel treatments, even when there are no randomized controlled trial data to support the new option. The perception that medicine is advancing and "new must be better" can be difficult to dispel. Robot-assisted laparoscopic prostatectomy is an example of how the high preoperative expectations of patients about a new treatment can lead to dissatisfaction with actual postoperative outcomes 32 .
The information priorities of patients are highly individual, and although most patients wish to participate in their treatment decision, there is wide variation with respect to needs both between and within countries 33 . The literature is dominated by pre-and post-treatment questionnaire studies. Such studies are easy for patients to comprehend, and they provide an overview of trends. However, they fail to examine the true decision-making "tradeoff process" in choosing a cancer treatment. Objective methods of assessing that decision-making process are available (Table i summarizes research methods for determining patient preference), and it is likely that those methods will be increasingly used in future studies.
Patient preference and selection of a treatment does not occur in isolation: partners and other family members play influential roles 35 . Those parties are involved in information gathering and may take active roles in decision-making 19 . The patient's partner has been demonstrated to be more able than the specialist responsible for the patient's care to accurately identify the patient's quality-of-life preferences 36 . It is increasingly recognized that the side effects of treatment burden partners (sometimes more than the patients themselves), particularly side effects relating to urinary and sexual function 37 .
A partner experiences their loved one's illness vicariously, and thus her or his beliefs are likely to exert a significant influence on the patient's adjustment after treatment. In certain circumstances the partner may, in fact, be better able (or perhaps more willing) than the patient himself to identify or articulate the relevant trade-off issues in treatment selection. Patients with spouses who have high treatment control beliefs and who anticipate that the patient will recover quickly from treatment have been shown to report a better quality of life after treatment 38 . That finding affirms the influence not just of the patient's beliefs, but those of his partner, in the ultimate well-being of the patient. Little research has addressed the issue of decision regret for partners.
DECISION-MAKING AIDS
Decision-making aids prepare patients to participate in decisions that involve risks and benefits. A good decision will be made with confidence, will be compatible with the patient's (and, where appropriate, the partner's) beliefs and values, and will result in minimal regret at the time of the decision and in the future.
Decision-making aids are subtly different from educational tools, nomograms, or risk calculators. Educational tools are preparatory in nature and are used in anticipation of a decision that has already been, or yet to be, made. 41, 42 . Studies comparing patient management with and without dmas have consistently demonstrated that dmas increase the involvement of patients in their decision and facilitate a realistic perception of outcomes without apparent adverse effects 42 .
Decision-making aids for prostate cancer patients are available in written, video, and Internetbased formats to cater to diverse patient needs. The growth of the Internet since the early 2000s has led to a proliferation of dmas on the Web (Table iii provides examples of prostate cancer dmas available online) and enabled patients to share material about their diagnosis with family and friends. The Internet is advantageous, in that it is easily accessible to patients, relatives, and supporters at a convenient time, and material can be regularly updated, facilitating the shared decision-making process 43 .
Compared with simpler dmas, more detailed dmas seem to confer a small but significant improvement in knowledge gained by patients 42 . However, highly detailed or complex dmas may not be applicable to a broad population with varying literacy standards. Plain-language dmas with multicultural photos engage patients across diverse ethnicities, cultures, educational levels, and socioeconomic groups in the shared decision-making process. Decision-making aids in this format increase knowledge about prostate cancer treatment options without being perceived as being "dumbed down" 43 . Decision aids that express the probabilities of various decision sequelae in numbers rather than words lead to more accurate risk perceptions by patients in general 41, 42 .
"Explicit values clarification" is a beneficial concept that has recently been included in dmas. Values clarification aims to assist patients to combine their beliefs with their values by helping them either discover that they have particular values or learn the relative impact of competing values. "Explicit values clarification" describes the process of a patient performing an action-such as moving a bar or typing numbers-to reflect the relative impact of particular values on their decision. Randomized controlled trial data suggest that, when used as part of a dma, values clarification exercises better prepare the patient for decision-making and lessen regret after the decision is made. The inclusion of explicit values clarification into a dma results in even more patients achieving decisions that are informed and consistent with their own values 44 .
Although dmas are associated with improved patient-doctor communication and patient satisfaction 42 , the most appropriate time and manner for introducing dmas to patients has not been rigorously established. Decision-making aids have been demonstrated to have a variable effect on physician consultation length. A Cochrane review indicated that a median of 2.5 minutes (range: -8 minutes to +24 minutes) might be added to consultation time 42 . However, if the patient is overwhelmed by the impact of a new cancer diagnosis, an early consultation may be an inappropriate occasion to introduce a dma and encourage its use. At that point, a patient is unlikely to be able to make an informed decision or to formulate the information presented with or without assistance. Decision-making aids have demonstrated their greatest impact in undecided patients after diagnosis and the first consultation with a physician 45 . It therefore seems prudent to advise patients (and their partners, if they are involved) to use dmas after (rather than at) the consultation during which they are informed of a prostate cancer diagnosis. However, that approach requires a follow-up appointment with either the specialist or a qualified multidisciplinary team member to discuss the final treatment choice.
The Personal Patient Profile-Prostate (P3P) is a tailored decision-support tool available on the Web for patients diagnosed with localized prostate cancer. It was developed by a North American team and has transitioned from the pilot phase to a multicentre randomized controlled trial in American men 46, 47 . The dmas includes all of the applicable dimensions of the ipdas instrument. When the P3P was evaluated in a multicentre randomized controlled trial, the tool was highly rated for acceptability and usefulness. It reduced decisional conflict and facilitated selection of prostate cancer treatment consistent with the values and preferences of patients 47 .
DECISION REGRET
In the period immediately after a diagnosis of prostate cancer, patients are focused on survival and cancer eradication 48 , and decision regret therefore usually manifests only after treatment has commenced or been completed. Up to one third of patients express some regret 14, 25, 30 . Post-treatment decision regret has been correlated with passive involvement in the decision-making process and also subsequent changes in role and functioning in society, spirituality, financial difficulty, and pain 30, 49, 50 . 26 The decision aid reports the date of its last revision. 27 The decision aid reports whether the authors or their affiliations stand to gain or lose by the choices people make after using the decision aid.
28 The decision aid (or available technical document) reports readability levels.
Effectiveness
29 There is evidence that the decision aid (or an aid based on the same template) helps people learn about the available options and their features.
30 There is evidence that the decision aid (or one based on the same template) improves the match between the features that matter most to the informed person and the option that is chosen.
Decision regret is recognized to increase significantly with time since treatment. That trend has been associated with limitations in activity because of incontinence and changes in sexual dysfunctionsymptoms that occur in prostate cancer patients, particularly after radical prostatectomy 51 .
The effect of dmas on post-treatment regret is poorly defined. In the largest randomized controlled trial evaluating the use of the P3P dma in American men, use of the aid did not predict decision regret 52 . Conversely, in a smaller randomized controlled trial in Scotland, investigators did find lower regret scores 6 months after treatment in the group that used the dma compared with a control group that did not 53 . Another multicentric randomized controlled trial compared two versions of a decision aid, one with structured information and one with values clarification exercises, on subsequent decision regret. Patients were reviewed immediately after reaching their decision, 3 months post treatment, and more than 1 year later. In both groups decisional conflict decreased after the dma was used, but the values clarification group reported better preparation for decision-making. Decision regret did not differ between the groups at the 3-month follow-up, but regret was lower for the values clarification exercises group at more than 1 year after follow-up 44 . Further research is required to truly ascertain the effect of dmas on treatment regret.
SUMMARY
Shared decision-making for prostate cancer treatment must involve both the patient and his partner. A patient's knowledge and understanding of his diagnosis and treatment options should not be assumed to be adequate after a consultation during which he is informed of both. Although educational aids are useful, comprehension and inter pretation by patients of the infor mation contained in the material may differ from what a health care professional expects. As a treatment adjunct, dmas permit patients (and their partners and family members, if they are involved) to explore their values and beliefs about treatment in a non-pressured environment. Decision-making aids meeting ipdas standards should be offered to all patients after their diagnosis and before a final treatment decision is made, especially when the patients seem undecided at the consultation after diagnosis. Health care professionals must recognize that treatment regret may manifest despite fully informed consent, and they must have appropriate strategies in place within their organizations for dealing with that regret.
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